This trial is active, not recruiting.

Conditions recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma
Treatments laboratory biomarker analysis, palbociclib
Phase phase 2/phase 3
Target CDK4
Sponsor Southwest Oncology Group
Collaborator National Cancer Institute (NCI)
Start date June 2014
End date June 2017
Trial size 42 participants
Trial identifier NCT02785939, NCI-2014-01380, S1400C, U10CA180888


This phase II trial studies how well palbociclib works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the cyclin dependent kinase 4/6 (CDK4/6) biomarker. CDK4/6 can cause tumor cells to grow more quickly. Palbociclib may decrease the activity of CDK4/6 and may be able to shrink tumors.

United States Alaska, California, Colorado, Delaware, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, and 22 other states
Other Countries No locations recruiting